

## Akums introduces DCGI approved medication for treatment of resistant hypertension

02 May 2024 | News

### **Fixed-dose of triple medications as a single pill to improve patient's dose compliance leading to better long-term BP control**

Hypertension, a pervasive health challenge associated with significant mortality and long-term morbidity, remains a formidable obstacle in healthcare worldwide.

Recognising the pressing need for solutions, Akums Drugs and Pharmaceuticals has introduced Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets, a fixed-dose combination (FDC) medication for the management of uncontrolled essential hypertension with stable coronary artery disease. This FDC integrates the therapeutic benefits of three well-established medications into a single, convenient tablet, offering a comprehensive approach to blood pressure control.

With the approval from the Drugs Controller General of India (DCGI), Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets represent an advancement in cardiovascular care.

By combining the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and beta-adrenergic blockers, this FDC offers a comprehensive approach to blood pressure control. "We believe that this formulation has the potential to improve the way we manage hypertension" said Sanjeev Jain, MD, Akums Drugs and Pharmaceuticals.

The individual mechanism of action of each component contributes to the FDC's efficacy in hypertension management. Amlodipine, by blocking voltage-dependent L-type calcium channels, induces vasodilation and decreases vascular smooth muscle contractility, thereby lowering blood pressure. Telmisartan selectively inhibits the angiotensin II AT1 receptor subtype, promoting blood vessel relaxation. Metoprolol (ER), a cardio-selective beta-1-adrenergic receptor inhibitor, reduces cardiac output through negative inotropic and chronotropic effects.